CLAIMS

1. A pharmaceutical composition comprising S-ketamine hydrochloride and water; wherein the pharmaceutical composition does not contain an antimicrobial preservative, and wherein the composition further contains a penetrating agent which is tauroursodeoxycholic acid.

2. The pharmaceutical composition according to Claim 1, which
(i) additionally contains a buffer; and/or
(ii) has a pH value within the range of from 4.0 to 6.5.

3. The pharmaceutical composition according to Claim 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 100 mg/mL to eq. 200 mg/mL, based on the total volume of the composition; or
wherein the S-ketamine hydrochloride is present in a concentration in the range of eq. 125 mg/mL to eq. 150 mg/mL, based on the total volume of the composition; or
wherein the S-ketamine hydrochloride is present in a concentration in the range of 126 mg / mL to 162 mg/mL, based on the total volume of the composition.

4. The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition is formulated for nasal administration.

5. The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition further contains a buffer.

6. The pharmaceutical composition according to Claim 5, wherein the buffer is 1N NaOH.

7. The pharmaceutical composition according to Claim 5, wherein the buffer is present in an amount sufficient to adjust the pH of the pharmaceutical composition to a pH in the range of from pH 3.5 to pH 6.5, or
wherein the buffer is present in an amount sufficient to adjust the pH of the composition to a pH in the range of from pH 4.5 to pH 5.5.

8. The pharmaceutical composition according to Claim 1, wherein the pharmaceutical composition exhibits a shelf-life under accelerated storage conditions of at least 3 months.

9. The pharmaceutical composition according to Claim 1; wherein the pharmaceutical composition further contains tauroursodeoxycholic acid in a concentration in the range of from 1 mg/mL to 25 mg/mL, based on the total volume of the composition.

10. The pharmaceutical composition according to Claim 2; wherein the pharmaceutical composition further contains tauroursodeoxycholic acid in a concentration in the range of from 5 mg/mL to 10 mg/mL.

11. A pharmaceutical dosage form comprising the pharmaceutical composition according to any of claims 1.

12. The dosage form according to claim 11, which is adapted for nasal administration.

13. The pharmaceutical composition according to Claim 1 or the pharmaceutical dosage form according to Claim 11 for use in the treatment of depression.

14. The pharmaceutical composition or the pharmaceutical dosage form for use according to claim 13, wherein the depression is selected from the group consisting of major depressive disorder, unipolar depression, treatment-refractory depression, resistant depression, anxious depression and bipolar depression,
preferably wherein the depression is selected from the group consisting of resistant depression or treatment refractory depression.